Novadiscovery has received funding from Sanofi and will support the French major’s COVID-19 efforts with its virtual JINKO clinical trial platform.
France’s Novadiscovery has raised €2.5m ($3.03m) in a series A2 financing from Sanofi to further develop its proprietary JINKO in silico or virtual clinical trial simulation platform and expand into the US market.
Nova will collaborate with Sanofi to develop a COVID-19 disease model to support the latter’s efforts in tackling the pandemic...
Create an account to read this article
Already a subscriber?
Big pharma is increasingly looking east to restock its pipelines, a process that is helping to forge a new generation of mid-sized R&D-based companies in China and is reflected in their stock price performance.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
